Inflammatory bowel disease (IBD) relates to two main diseases - ulcerative colitis (UC) and Crohn’s disease. Microscopic colitis is also a form of IBD but is less common.
IBD is a chronic (lifelong) condition in which parts of the gastrointestinal tract (GI tract) become inflamed. Where you get the inflammation depends on which type of IBD you have. UC only affects the colon, rectum and anus whereas Crohn’s disease can affect any part of the GI tract - from mouth to anus.
Around 300,000 people have IBD in the UK and it can hugely affect a person’s quality of life.
Both UC and Crohn’s disease are treated and managed with medication. However, in some cases medication isn’t effective and people need surgery to remove portions of their bowels.
Symprove was recently assessed in a randomised, double-blind, placebo-controlled trial with 80 UC patients. The results showed there were significant changes in the calprotectin levels in the patients treated with Symprove – 76% had a reduced calprotectin level after 4 weeks.
Watch the following video about the impact of ulcerative colitis on Chris’ life and how Symprove has helped him.
Welcome to Symprove Holdings Limited scientific website.
To access this site, please confirm that you are a healthcare professional, scientist or journalist.